**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 77803

**Manuscript Type:** CASE REPORT

**Drug-induced lung injury caused by acetaminophen in a Japanese woman: A case report**

Fujii M *et al*. Drug-induced lung injury caused by acetaminophen

Masayoshi Fujii, Tsuneaki Kenzaka

**Masayoshi Fujii,** Department of Internal Medicine, Toyooka Public Hospital, Toyooka 668-8501, Japan

**Masayoshi Fujii, Tsuneaki Kenzaka,** Department of Internal Medicine, Hyogo Prefectural Tamba Medical Center, Tamba 669-3495, Japan

**Tsuneaki Kenzaka,** Division of Community Medicine and Career Development, Kobe University Graduate School of Medicine, Kobe 652-0032, Japan

**Author contributions:** Fujii M managed the case and revised and corrected the manuscript; Kenzaka T assisted with redaction, correction, and reconstruction of the manuscript; all authors read and approved the final manuscript.

**Corresponding author: Tsuneaki Kenzaka, MD, PhD, Professor,** Division of Community Medicine and Career Development, Kobe University Graduate School of Medicine, 2-1-5 Arata-cho, Hyogo-ku, Kobe 652-0032, Japan. smile.kenzaka@jichi.ac.jp

**Received:** May 21, 2022

**Revised:** July 2, 2022

**Accepted:** August 11, 2022

**Published online:**

**Abstract**

BACKGROUND

All drugs have the potential to cause drug-induced lung injury both during and after drug administration. Acetaminophen has been reported to cause drug-induced lung injury, although this is extremely rare. Herein, we present an extremely rare case of acetaminophen-induced pneumonia.

CASE SUMMARY

A healthy 35-year-old Japanese woman visited a neighborhood clinic with complaints of fever and malaise following a tick bite. Her treatment included 1,500 mg acetaminophen (Caronal®) and subsequently minocycline (200 mg) and acetaminophen (2,000 mg; Caronal®) daily when her condition did not improve; the patient was eventually hospitalized. The patient’s chest computed tomography (CT) revealed consolidation and ground-glass opacities in the right middle and lower lobes. Minocycline was shifted to sulbactam/ampicillin. However, her fever did not improve during follow-up, and her chest CT revealed extensive ground-glass opacities in the right middle and lower lobes and thick infiltrative shadows in the bilateral basal areas. Drug-induced lung injury was suspected; hence, acetaminophen was discontinued. The fever resolved immediately, and inflammatory response and respiratory imaging findings improved. A drug-induced lymphocyte stimulation test was performed against acetaminophen (Caronal®), and significant proliferation of lymphocytes was noted only for acetaminophen (stimulation index, 2.1).

CONCLUSION

Even common drugs such as over-the-counter drugs can cause drug-induced lung damage.

**Key Words:** Acetaminophen; Computed tomography; Pneumonia; Fever; Tick bite; Case report

Fujii M, Kenzaka T. Drug-induced lung injury caused by acetaminophen in a Japanese woman: A case report. *World J Clin Cases* 2022; In press

**Core Tip:** We present an extremely rare case of acetaminophen-induced lung injury. Even common drugs, including over-the-counter drugs, can cause lung injury, warranting consideration when evaluating emergent lung disease.

**INTRODUCTION**

All drugs have the potential to cause drug-induced lung injury both during and after drug administration. Although this is extremely rare, acetaminophen can also reportedly cause drug-induced lung injury[1]. Drug-induced lung disease is associated with various pathophysiologic and clinical presentations and syndromes. However, certain clinical patterns of pneumonia are likely to occur with specific types of drugs, as previously reported[2]. The drug provocation test is the gold standard for confirming the diagnosis of drug hypersensitivity[3]. However, this test is associated with a high risk of severe side effects; therefore, its use is controversial.

In clinical practice, resolution of symptoms after suspected drug exposure cessation is usually sufficient for diagnosis without the need for rechallenge[4]. The diagnosis of drug-induced lung injury is based on a combination of information, including symptoms, physical examinations, drug intake and medical history, and imaging and pathological findings[5].Acetaminophen-induced lung injury generally presents as a clinical form of drug-induced eosinophilic pneumonia[1,2]. Acetaminophen is one of the most frequently used drugs, and a few studies have reported acetaminophen-induced lung injury. Herein, we describe the clinical characteristics of acetaminophen-induced pneumonia in a Japanese woman.

**CASE PRESENTATION**

***Chief complaints***

A healthy 35-year-old Japanese woman visited a neighborhood clinic 7 d before hospitalization with complaints of fever and malaise.

***History of present illness***

She was bitten by a tick while cleaning her house 9 d before hospitalization.

***History of past illness***

Nothing in particular.

***Personal and family history***

Her personal and family history was unremarkable. On admission, she had no history of smoking or allergies as well.

***Physical examination***

On physical examination at admission, the patient’s temperature was 37.3 °C, blood pressure was 93/52 mmHg, pulse rate was 72 beats/min, respiration rate was 16 breaths/min, and peripheral capillary oxygen saturation level was 96% (room air).

Respiratory and cardiovascular tests yielded clear results. Lymph nodes were palpable in the right axilla with two erythematous patches in the surrounding area.

***Laboratory examinations***

The patient’s peripheral white blood cell count was 8310/mm3, with 86.5% neutrophils, 11.7% lymphocytes, and 0.0% eosinophils. Her C-reactive protein level was 31.65 mg/dL. Tests for antibodies against *Orientia tsutsugamushi* showed negative findings. Blood culture results were also negative. Urine culture revealed *Enterococcus species* and coagulase-negative *Staphylococci* (Table 1)*.*

***Imaging examinations***

Chest radiography revealed interstitial shadows in the right lower lung (Figure 1A). Physical examination revealed a palpable right axillary lymph node; therefore, thoracoabdominal computed tomography (CT) was performed for deep lymph node evaluation. Chest CT revealed consolidation and ground-glass opacities in the right middle and lower lobes (Figure 2A). Minocycline was discontinued because of the low risk of rickettsial infection. Acetaminophen (Caronal®) 2000 mg was administered orally, and acetaminophen (Acelio®) 500 mg was administered intravenously for symptomatic treatment.

**FURTHER DIAGNOSTIC WORK-UP**

We suspected pyelonephritis; based on the antimicrobial susceptibility of urine culture results, we administered sulbactam/ampicillin 3 g every 6 h for 3 d. However, a fever of > 38 °C persisted. On day 4 of hospitalization, repeat chest radiography revealed worsening of interstitial shadows in the right lower lung (Figure 1B), and chest CT revealed extensive ground-glass opacities mainly in the right middle and lower lobes and thick infiltrative shadows in the bilateral basal areas. In addition, thickening of the interlobular septum, bronchovascular bundles, and bilateral pleural effusions suggested eosinophilic pneumonia or organizing pneumonia (Figure 2B and C).

**FINAL DIAGNOSIS**

We suspected atypical pneumonia or interstitial pneumonia and investigated the patient for infections and collagen diseases; however, serological tests for common causative agents of atypical pneumonia and autoimmune disease-associated autoantibodies revealed negative results (Table 1).

**TREATMENT**

The patient was treated with acetaminophen 1500 mg (Caronal®); however, her condition did not improve. Three d before hospitalization, she presented with a fever of 38 °C and a lack of appetite.We suspected rickettsial infection at this time and initiated daily administration of minocycline (200 mg) and acetaminophen (2,000 mg; Caronal®); however, her condition did not improve; therefore, she was admitted to our hospital.

Atypical pneumonia was considered in the differential diagnosis, and azithromycin 500 mg was administered as the first dose, followed by 250 mg every 24 h for 5 d after the second dose. Since we suspected drug-induced lung injury, acetaminophen was discontinued and replaced with a nonsteroidal anti-inflammatory drug, resulting in resolution of fever on day 6 of hospitalization and improvement in inflammatory response and pulmonary imaging findings, without immunosuppressive or anti-inflammatory therapy, on day 10 of hospitalization (Figure 2D). Hypoxemia was not observed during hospitalization; therefore, the drug was discontinued, and the patient was discharged on day 13 of hospitalization. The drug-induced lymphocyte stimulation test (DLST) was performed against acetaminophen (Caronal®) and minocycline post-discharge, and negative results were obtained for minocycline, with significant proliferation of lymphocytes noted only for acetaminophen and a stimulation index of 2.1. The sensitivity of the DLST is reported to be 60%-70%, and its specificity is 85%; however, false-positive results have also been reported; therefore, the DLST was only intended to assist the diagnostic process[6,7].

**OUTCOME AND FOLLOW-UP**

The diagnostic criteria for drug-induced lung injury outlined by Camus *et al*[2] are as follows: (1) Correct identification of the drug; (2) Singularity of the drug; (3) Temporal eligibility; (4) Characteristic clinical, imaging, bronchoalveolar lavage, and pathologic patterns of reaction to the specific drug; and (5) Exclusion of other causes of interstitial lung disease (ILD). The patient was healthy, had no history of ILD, and had a new history of acetaminophen and minocycline exposure. Minocycline was administered for 3 d and discontinued on admission. The patient developed drug-induced eosinophilic pneumonia-like imaging findings on day 4 of hospitalization. The imaging findings worsened gradually after discontinuation of minocycline until day 4 of hospitalization, suggesting that minocycline was unlikely to have influenced the patient’s disease. On the other hand, symptoms and imaging findings rapidly improved after discontinuation of acetaminophen on day 4 of hospitalization. In addition, other potential causes of ILD, such as infections and collagen diseases, were excluded. Although the drug provocation test was not performed, all diagnostic criteria were met, and acetaminophen-induced pneumonia was diagnosed. No recurrence of ILD was observed in the last 4 years since the patient first visited our clinic.

**DISCUSSION**

We present an extremely rare case of acetaminophen-induced lung injury. Although the drug provocation test was not performed in this case, we diagnosed acetaminophen-induced lung injury based on the history of drug administration, clinical course, and DLST results. The imaging findings suggested eosinophilic pneumonia; however, since bronchoalveolar lavage was not performed, the diagnosis could not be confirmed. Acetaminophen is an extremely rare causative agent of drug-induced pneumonia[1,2,8,9]. Acetaminophen-induced lung injury has been reported in 16 patients, excluding the patient in this case, as indexed in PubMed (Table 2)[10-24]. Among the 17 patients, including our patient, 12 (70.6%) were female patients, five (29.4%) were male patients, and 16 (94.1%) were Japanese patients. Only one case of a Caucasian patient has been reported in another country. The patients’ median age was 64 years (interquartile range [IQR], 45-72 years). Acetaminophen and over-the-counter drugs containing acetaminophen were the causative agents in nine (52.9%) and eight (47.1%) patients, respectively. Seven (41.1%) patients met the diagnostic criteria for drug-induced eosinophilic pneumonia[1,8]. The median time (in d) between drug exposure and the onset of respiratory symptoms was 5 d (IQR, 3-11 d); the onset was often relatively short-lived after the initiation of medication. In all patients, the causative drug was discontinued at the start of treatment, and the condition of four (23.5%) patients improved with discontinuation of the drug alone, while 13 (76.5%) patients required corticosteroids. Two patients required ventilation management, and all patients were discharged with good outcomes.

There are several reasons for the relatively high number of reports of acetaminophen-induced lung injury in Japan. First, racial differences may exist, such that drug-induced lung injury has been associated with ethnicity. The incidence and mortality rates of drug-induced lung injuries are higher in Japan than in other countries[5]. These ethnicity-based differences suggest possible variations in the genes related to lung fragility in Japanese patients[25]. The *MUC4* gene is suspected to be the causative gene and remains under investigation. Furthermore, a large number of CT examinations than those performed in other countries[26] may affect these rates.

Several drugs can induce lung injury both during and after administration[2]. Acetaminophen is a frequently prescribed drug in clinical practice and is a constituent of many medical and over-the-counter drugs. The incidence of drug-induced lung injury has been reported for acetaminophen alone and for acetaminophen-containing combination drugs and over-the-counter drugs. In previous reports, eight (47.1%) patients were suspected of having acetaminophen-induced lung injury at the time of initial diagnosis, and the drug was discontinued[24]. The eight patients, including the patient in this case, were not diagnosed with acetaminophen-induced lung injury at the time of initial diagnosis and continued to use it. Acetaminophen is not easily identified as a cause of drug-induced lung injury because of the rarity of the injury and the tendency of patients to withhold information on frequently or recently used drugs. In many cases, patients recover spontaneously on discontinuing the drug; however, a severe course is noted in some cases. Therefore, in this case, acetaminophen should have been discontinued at an early stage. It is important to remember that even common drugs, including over-the-counter drugs, can cause drug-induced lung injury.

**CONCLUSION**

We have presented an extremely rare case of acetaminophen-induced lung injury. Even common drugs, including over-the-counter drugs, can cause lung injury and must be considered when evaluating emergent lung disease.

**REFERENCES**

1 **Allen JN**. Drug-induced eosinophilic lung disease. *Clin Chest Med* 2004; **25**: 77-88 [PMID: 15062599 DOI: 10.1016/S0272-5231(03)00141-2]

2 **Camus P**, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. *Respiration* 2004; **71**: 301-326 [PMID: 15316202 DOI: 10.1159/000079633]

3 **Aberer W**, Bircher A, Romano A, Blanca M, Campi P, Fernandez J, Brockow K, Pichler WJ, Demoly P; European Network for Drug Allergy (ENDA); EAACI interest group on drug hypersensitivity. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. *Allergy* 2003; **58**: 854-863 [PMID: 12911412 DOI: 10.1034/j.1398-9995.2003.00279.x]

4 **De Giacomi F**, Vassallo R, Yi ES, Ryu JH. Acute Eosinophilic Pneumonia. Causes, Diagnosis, and Management. *Am J Respir Crit Care Med* 2018; **197**: 728-736 [PMID: 29206477 DOI: 10.1164/rccm.201710-1967CI]

5 **Ushiki A,** Hanaoka M. Clinical characteristics of DLI: What are the clinical features of DLI? In: Hanaoka M, Nakamura H, Aoshiba K, editors. Drug-Induced Lung Injury. Respiratory Disease Series: Diagnostic Tools and Disease Managements. Singapore: Springer, 2018 [cited 20 April 2022]. Available from: https://link.springer.com/book/10.1007/978-981-10-4466-3

6 **Pichler WJ**, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. *Allergy* 2004; **59**: 809-820 [PMID: 15230812 DOI: 10.1111/j.1398-9995.2004.00547.x]

7 **Ono E**, Miyazaki E, Matsuno O, Nureki S, Okubo T, Ando M, Kumamoto T. Minocycline-induced acute eosinophilic pneumonia: controversial results of lymphocyte stimulation test and re-challenge test. *Intern Med* 2007; **46**: 593-595 [PMID: 17473496 DOI: 10.2169/internalmedicine.46.6235]

8 **Solomon J**, Schwarz M. Drug-, toxin-, and radiation therapy-induced eosinophilic pneumonia. *Semin Respir Crit Care Med* 2006; **27**: 192-197 [PMID: 16612770 DOI: 10.1055/s-2006-939522]

9 **Bartal C**, Sagy I, Barski L. Drug-induced eosinophilic pneumonia: A review of 196 case reports. *Medicine (Baltimore)* 2018; **97**: e9688 [PMID: 29369189 DOI: 10.1097/MD.0000000000009688]

10 **Kitaguchi S**, Miyazawa T, Minesita M, Doi M, Takahashi K, Yamakido M. [A case of acetaminophen-induced pneumonitis]. *Nihon Kyobu Shikkan Gakkai Zasshi* 1992; **30**: 1322-1326 [PMID: 1405111]

11 **Kudeken N**, Kawakami K, Kakazu T, Takushi Y, Kakazu T, Fukuhara H, Nakamura H, Kaneshima H, Saito A, Toda T. A case of acetaminophen-induced pneumonitis. *Nihon Kyobu Shikkan Gakkai Zasshi* 1993; **31**: 1585-1590 [PMID: 8121097]

12 **Nakatsumi Y**, Nakatsumi T, Bandou T, Kumabasiri I, Araki I, Ueno T, Nomura M, Fujimura M, Matsuda T. A case of pneumonitis induced by PL granules. *Nihon Kyobu Shikkan Gakkai Zasshi* 1994; **32**: 1209-1212 [PMID: 7853781]

13 **Nomura M**, Fujimura M, Matsuda T, Kitagawa M. Drug-induced pneumonitis associated PABRON-GOLD. *Nihon Kyobu Shikkan Gakkai Zasshi* 1997; **35**: 72-76 [PMID: 9071160]

14 **Kawano T**, Ogushi F, Maniwa K, Nakamura Y, Haku T, Sone S. A case of rheumatoid lung exacerbated by acetaminophen-induced pneumonitis. *Nihon Kyobu Shikkan Gakkai Zasshi* 1997; **35**: 1113-1118 [PMID: 9465625]

15 **Akashi S**, Tominaga M, Naitou K, Fujisawa N, Nakahara Y, Hiura K, Hayashi S. Two cases of acetaminophen-induced pneumonitis. *Nihon Kyobu Shikkan Gakkai Zasshi* 1997; **35**: 974-979 [PMID: 9396256]

16 **Nakajima M**, Yoshida K, Miyashita N, Niki Y, Matsushima T. Acetaminophen-induced pneumonitis. *Nihon Kokyuki Gakkai Zasshi* 1998; **36**: 973-977 [PMID: 9916483]

17 **Ikeuchi H**, Sando Y, Tajima S, Sato M, Hosono T, Maeno T, Maeno Y, Suga T, Kurabayashi M, Nagai R. PL granule-induced pneumonia requiring mechanical ventilation. *Nihon Kokyuki Gakkai Zasshi* 2000; **38**: 682-686 [PMID: 11109805]

18 **Hiramatsu K**, Takeda Y, Yamauchi Y, Suzuki T, Kudo K. A case of eosinophilic pneumonia induced by Pelex granule. *Nihon Kokyuki Gakkai Zasshi* 2002; **40**: 220-224 [PMID: 11974896]

19 **Nakayama S**, Mukae H, Ishimatsu Y, Sugiyama K, Ide M, Ishimoto H, Hisatomi K, Ishii H, Abel K, Ozono Y, Kohno S. A case of rheumatoid lung complicated by SELAPINA-induced pneumonia. *Nihon Kokyuki Gakkai Zasshi* 2006; **44**: 858-863 [PMID: 17144587]

20 **Anan E**, Shirai R, Kai N, Ishii H, Hirata N, Kishi K, Tokimatsu I, Nakama K, Hiramatsu K, Kadota J. Acute eosinophilic pneumonia caused by several drugs including ibuprofen. *Nihon Kokyuki Gakkai Zasshi* 2009; **47**: 443-447 [PMID: 19514510]

21 **Kato H**, Ogasawara T, Kimura R, Paku C, Wakayama H, Suzuki M. A case of drug-induced pneumonitis due to a cold remedy. *Nihon Kokyuki Gakkai Zasshi* 2010; **48**: 619-624 [PMID: 20803982]

22 **Sasaki A,** Murata K, Sato Y, Wada A, Takamori M. A case of drug-induced eosinophilic pneumonia caused by acetaminophen that was diagnosed by accidental readministration of the combination remedy for colds. *Nihon Kokyuki Gakkai Zasshi* 2014; 3: 813-817 [cited 20 April 2022]. Available from: https://mol.medicalonline.jp/library/journal/download?GoodsID=ci6respo/2014/000306/014&name=0813-0817j&UserID=1100001359-AA&base=jamas\_pdf

23 **Saint-Pierre MD**, Moran-Mendoza O. Acetaminophen Use: An Unusual Cause of Drug-Induced Pulmonary Eosinophilia. *Can Respir J* 2016; **2016**: 4287270 [PMID: 27445539 DOI: 10.1155/2016/4287270]

24 **Ueda T,** Araya T, Uchida Y, Kimura H, Kasahara K, Kita T. A case of acetaminophen-induced eosinophilic pneumonia. *Nihon Kokyuki Gakkai Zasshi* 2019; **8**: 42-46 [cited 20 April 2022]. Available from: https://mol.medicalonline.jp/library/journal/download?GoodsID=ci6respo/2019/000801/010&name=0042-0046j&UserID=1100001359-AA&base=jamas\_pdf

25 **Anan K**, Ichikado K, Kawamura K, Johkoh T, Fujimoto K, Suga M. Clinical characteristics and prognosis of drug-associated acute respiratory distress syndrome compared with non-drug-associated acute respiratory distress syndrome: a single-centre retrospective study in Japan. *BMJ Open* 2017; **7**: e015330 [PMID: 29122783 DOI: 10.1136/bmjopen-2016-015330]

26 **OECD Health Statistics 2021**. [cited 20 April 2022]. Available from: https://www.oecd.org/els/health-systems/health-data.htm

**Footnotes**

**Informed consent statement:** The patient provided written informed consent for the publication of this case report and accompanying images. A copy of the consent form is available for review by the editor of this journal.

**Conflict-of-interest statement:** All authors declare that they have no conflict of interest to disclose.

**CARE Checklist (2016) statement:** All authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016)

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** May 21, 2022

**First decision:** June 27, 2022

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** Japan

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B


Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Bao S, Australia; Jian X, China **S-Editor:** Wang LL **L-Editor:** A **P-Editor:** Wang LL

**Figure Legends**



**Figure 1 Chest radiography images.** A: Chest radiography at admission shows right lower lung interstitial shadows; B: Chest radiography on day 4 of hospitalization shows worsened right lower lung interstitial shadows.



**Figure 2 Chest computed tomography images.** A: Chest computed tomography at admission reveals right middle and lower lobar consolidation and ground-glass opacity; B and C: Chest computed tomography on day 4 of hospitalization shows extensive ground-glass opacity, mainly in the right middle and lower lobes, and thick bilateral basal infiltrative shadows. In addition, thickening of the interlobular septum and bronchovascular bundles, and bilateral pleural effusion, suggestive of eosinophilic or organizing pneumonia, are seen; D: Chest computed tomography on day 10 of hospitalization shows improvement of ground-glass opacity and infiltrative shadows.

**Table 1 Laboratory and serological test findings representative of atypical or interstitial pneumonia at admission**

|  |  |  |
| --- | --- | --- |
| **Parameter** | **Recorded value** | **Standard range** |
| White blood cell count | 8310/µL | 4500-7500/µL |
| Neutrophil | 86.50% |  |
| Lymphocyte | 11.70% |  |
| Monocyte | 1.70% |  |
| Eosinophils | 0.00% |  |
| Hemoglobin | 11.8 g/dL | 11.3-15.2 g/dL |
| Platelet count | 23.2 × 103/µL | 13-35 × 103/µL |
| Total protein | 6.9 g/dL | 6.9-8.4 g/dL |
| Albumin | 3.5 g/dL | 3.9-5.1 g/dL |
| Total bilirubin | 0.7 mg/dL | 0.2-1.2 mg/dL |
| Aspartate aminotransferase | 31 U/L | 11-30 U/L |
| Alanine aminotransferase | 26 U/L | 4-30 U/L |
| Lactase dehydrogenase | 368 U/L | 109-216 U/L |
| Blood urea nitrogen | 9.6 mg/dL | 8-20 mg/dL |
| Creatinine | 0.5 mg/dL | 0.63-1.03 mg/dL |
| Sodium | 135 mEq/L | 135-145 mEq/L |
| Potassium | 4.2 mEq/L | 3.6-5.2 mEq/L |
| Chlorine | 98 mEq/L | 98-108 mEq/L |
| C-reactive protein | 31.65 mg/L | ≤1.0 mg/L |
| Procalcitonin | 0.66 ng/mL | ≤0.3 ng/mL |
| KL-6 | 205 U/mL | ≤500 U/mL |
| Surfactant protein A | 105.9 ng/mL | ≤43.8 ng/mL |
| Surfactant protein D | 105.3 ng/mL | ≤110 ng/mL |
| C3 | 136 mg/dL | 86-160 mg/dL |
| C4 | 28.7 mg/dL | 17-45 mg/dL |
| IgG | 1137 mg/dL | 870-1700 mg/dL |
| IgA | 193 mg/dL | 110-410 mg/dL |
| IgM | 134 mg/dL | 35-220 mg/dL |
| ACE | 15.2 U/mL | 8.3-21.4 U/mL |
| Antinuclear antibody | < 40 | < 40 |
| RF | < 3 U/mL | 0-15 U/mL |
| Anti-CCP antibody | 0.8 U/mL | < 5 U/mL |
| Anti-Ro/SS-A antibody | Negative | Negative |
| Anti-La/SS-B antibody | Negative | Negative |
| Anti-Jo-1 antibody | Negative | Negative |
| Anti-ARS antibody | Negative | Negative |
| PR3-ANCA | Negative | Negative |
| MPO-ANCA | Negative | Negative |
| *Orientia tsutsugamushi* Karp IgG | < 10 | < 10 |
| *Orientia tsutsugamushi* Karp IgM | < 10 | < 10 |
| *Orientia tsutsugamushi* Kato IgG | < 10 | < 10 |
| *Orientia tsutsugamushi* Kato IgM | < 10 | < 10 |
| *Orientia tsutsugamushi* Gilliam IgG | < 10 | < 10 |
| *Orientia tsutsugamushi* Gilliam IgM | < 10 | < 10 |
| *C. pneumoniae* IgG | Negative | Negative |
| *C. pneumoniae* IgA | Negative | Negative |
| CMV-IgG | 199.7 | 0.0-1.0 |
| CMV-IgM | < 0.85 | 0-0.7 |
| *M. pneumoniae* PCR of the sputum | Negative | Negative |
| Urine Legionella antigen testing | Negative | Negative |
| Beta-D-glucan assay | 9.0 pg/mL |  |
| Aspergillus IgG | Negative | Negative |
| Anti-*Trichosporon asahii* antibody | Negative | Negative |

ACE: Angiotensin I-converting enzyme; ANCA: Antineutrophil cytoplasmic antibodies; ARS: Aminoacyl tRNA synthetase; *C. pneumoniae: Chlamydia pneumoniae*; CCP: Cyclic citrullinated peptide; CMV: Cytomegalovirus; Ig: Immunoglobulin; KL-6: Sialylated carbohydrate antigen KL-6; *M. pneumoniae: Mycoplasma pneumoniae*; MPO: Myeloperoxidase; PCR: Polymerase chain reaction; PR3: Proteinase 3; RF: Rheumatoid factor.

**Table 2 Clinical characteristics of patients with reported acetaminophen-induced lung injury**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Case** | **Sex** | **Age (years)** | **Ethnicity** | **Drugs** | **Symptoms** | **Time between drug use and presentation (d)** | **Time between initial diagnosis and drug discontinuation (d)** | **Treatment** | **Outcome** | **Ref.** |
| 1 | Female | 20 | Japanese | Acetaminophen (Norshin®) | Fever, cough, and dyspnea | 2 | 0 | Drug discontinuation; Corticosteroids | Disease resolution | Kitaguchi *et al*[10], 1992 |
| 2 | Female | 63 | Japanese | Acetaminophen (Caronal®) | Cough and dyspnea | 8 | 10 | Drug discontinuation; Corticosteroids | Disease resolution | Kudeken *et al*[11], 1993 |
| 3 | Male | 45 | Japanese | Acetaminophen (PL Combination Granules®) | Fever, cough, and diarrhea | 4 | 0 | Drug discontinuation | Disease resolution | Nakatsumi *et al*[12], 1994 |
| 4 | Male | 75 | Japanese | Acetaminophen (Pabron gold®/Pabron S®) | Fever and dyspnea | 3 | 0 | Drug discontinuation; Corticosteroids | Disease resolution | Nomura *et al*[13], 1997 |
| 5 | Male | 57 | Japanese | Acetaminophen (PL Combination Granules® /Shin Lulu A Tablets®) | Fever, cough, and dyspnea | 11 | 8 months | Drug discontinuation; Corticosteroids | Respiration and disease resolution | Kawano *et al*[14], 1997 |
| 6 | Female | 64 | Japanese | Acetaminophen (Caronal®) | Fever, cough, and dyspnea | 19 | 8 | Drug discontinuation; Corticosteroids | Disease resolution | Akashi *et al*[15], 1997 |
| 7 | Female | 70 | Japanese | Acetaminophen (Caronal®) | Fever, cough, and dyspnea | 6 | 5 | Drug discontinuation; Corticosteroids | Disease resolution | Nakajima *et al*[16], 1998 |
| 8 | Female | 49 | Japanese | Acetaminophen (Benza Block SP®) | Fever and dyspnea | 5 | 5 | Drug discontinuation; Corticosteroids | Disease resolution | Nakajima *et al*[16], 1998 |
| 9 | Male | 72 | Japanese | Acetaminophen (PL Combination Granules®) | Fever and dyspnea | 1 | 0 | Drug discontinuation; Corticosteroids | Respiration and Disease resolution | Ikeuchi *et al*[17], 2000 |
| 10 | Male | 31 | Japanese | Acetaminophen (PL Combination Granules®) | Fever and cough | 13 | 31 | Drug discontinuation | disease resolution | Hiramatsu *et al*[18], 2002 |
| 11 | Female | 68 | Japanese | Acetaminophen (PL Combination Granules®) | Fever, cough, and dyspnea | 6 | 0 | Drug discontinuation; Corticosteroids, Cyclosporine | Disease resolution | Nakayama *et al*[19], 2006 |
| 12 | Female | 41 | Japanese | Acetaminophen (Ibuprofen®/Caronal®) | Fever, cough, and dyspnea | 3 | 0 | Drug discontinuation; Corticosteroids | Disease resolution | Anan *et al*[20], 2009 |
| 13 | Female | 84 | Japanese | Acetaminophen (Shin Lulu A Tablets s®) | Fever, cough, and dyspnea | 5 | 0 | Drug discontinuation; Corticosteroids | Disease resolution | Kato *et al*[21], 2010 |
| 14 | Female | 80 | Japanese | Acetaminophen (Caronal®) | Fever and dyspnea | 15 | 0 | Drug discontinuation; Corticosteroids | Disease resolution | Sasaki *et al*[22], 2014 |
| 15 | Female | 68 | Caucasian | Acetaminophen (Caronal®) | Cough and dyspnea | Months | Not specified | Drug discontinuation | Disease resolution | Saint-Pierre *et al*[23], 2016 |
| 16 | Female | 79 | Japanese | Acetaminophen (Caronal®) | Dyspnea | 2 | 0 | Drug discontinuation; Corticosteroids | Disease resolution | Ueda *et al*[24], 2019 |
| Present case | Female | 35 | Japanese | Acetaminophen (Caronal®) | Fever | 4 | 11 | Drug discontinuation | Disease resolution | - |